Results 11 to 20 of about 40,867 (262)

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval

Journal of Bone Oncology, 2022
Skeletal-related events (SREs) are complications of bone metastases and carry a significant patient and economic burden. Denosumab is a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor approved for SRE prevention in patients with multiple
Benoit Cadieux, Robert Coleman, Pegah Jafarinasabian, Allan Lipton, Robert Z. Orlowski, Fred Saad, Giorgio V. Scagliotti, Kazuyuki Shimizu, Alison Stopeck   +8 more
doaj   +2 more sources

Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw

Scientific Reports, 2023
Denosumab, an inhibitor of receptor activator of nuclear factor kappa-B ligand, reduces skeletal-related events (SREs) and is approved for solid tumors with bone metastases.
Pei-An Fu, Chin-Yao Shen, Shuen‑Ru Yang, Chun-Hui Lee, Hui-Wen Chen, Edward Chia-Cheng Lai, Wei-Pang Chung   +6 more
doaj   +2 more sources

Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases [PDF]

, 2005
PURPOSE: Bone metastases secondary to solid tumors increase the risk of skeletal-related events (SREs), including the occurrence of pathological fracture (PF), radiation to bone (RB), surgery to bone (SB), and spinal cord compression (SCC).
Roger von Moos, Jean-Jacques Body, Blair Egerdie, Alison Stopeck, Janet Brown, Lesley Fallowfield, Donald L. Patrick, Charles Cleeland, Danail Damyanov, Felipe Salvador Palazzo, Gavin Marx, Ying Zhou, Ada Braun, Arun Balakumaran, Yi Qian, RE Coleman, RE Coleman, R Moos von, S Vadhan-Raj, GR Mundy, GD Roodman, JA Ford, A Lipton, F Saad, LS Rosen, L Costa, CS Cleeland, K Lemay, CS Cleeland, M Maltoni, L Costa, CS Cleeland, R Moos von, L Costa, AT Stopeck, K Fizazi, DH Henry, D Henry, GV Scagliotti, A Lipton, CS Cleeland, KC Chung, DF Cella, K Webster, N Sathiakumar, N Sathiakumar, K Fizazi, M Yong, M Norgaard, K Cetin, C Nieder, E Chow, MR Smith, A Hussain, AM Abdulhalim, G Oster   +55 more
core   +5 more sources

Denosumab and incidence of type 2 diabetes among adults with osteoporosis: population based cohort study

British medical journal, 2023
Objective To estimate the effect of denosumab compared with oral bisphosphonates on reducing the risk of type 2 diabetes in adults with osteoporosis. Design Population based study involving emulation of a randomized target trial using electronic health ...
H. Lyu, S. Zhao, Licheng Zhang, Jie Wei, Xiao-xiao Li, Hui Li, Yi Liu, Pengbin Yin, V. Norvang, K. Yoshida, S. Tedeschi, C. Zeng, G. Lei, P. Tang, D. H. Solomon   +14 more
semanticscholar   +1 more source

Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review

ESMO Open, 2020
Objectives Giant cell tumour of bone (GCTB) is a rare tumour, generally managed with surgery. Treatment of the very rare unresectable advanced/metastatic GCTB is challenging and denosumab is the only current available medical option, an anti-RANKL ...
Alessandra Raimondi, Silvia Stacchiotti, Paolo G Casali, Noemi Simeone, Marco Guzzo, Massimo Maniezzo, Paola Collini, Carlo Morosi, Francesca Gabriella Greco, Anna Maria Frezza   +9 more
doaj   +1 more source

Does denosumab exert a protective effect against COVID-19? Results of a large cohort study

Frontiers in Endocrinology, 2023
IntroductionDenosumab is a monoclonal antibody blocking the receptor activator of nuclear factor kappa-B/receptor activator of nuclear factor kappa-B ligand (RANK/RANKL) pathway, thus inhibiting osteoclastogenesis.
Sara Cassibba, Silvia Ippolito, Silvia Pellegrini, Silvia Pellegrini, Roberto Trevisan, Roberto Trevisan, Alessandro Rossini   +6 more
doaj   +1 more source

Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review

Advances in Therapy, 2021
The fully human monoclonal antibody denosumab was approved for treatment of osteoporosis in 2010 on the basis of its potent antiresorptive activity, which produces clinically meaningful increases in bone mineral density (BMD) and reduces fracture risk at
D. Kendler, F. Cosman, R. Stad, S. Ferrari   +3 more
semanticscholar   +1 more source

Denosumab [PDF]

mAbs, 2009
Denosumab is an anti-receptor activator of nuclear factor (NF)-kappaB (RANK) ligand human monoclonal antibody studied as a treatment for postmenopausal osteoporosis (PMO) and bone destruction due to rheumatoid arthritis (RA) or metastatic cancers. As of February 2009, the candidate was undergoing US Food and Drug Administration review, and might be ...
openaire   +2 more sources

Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review

Journal of Clinical Medicine, 2021
Denosumab is a potent antiresorptive agent that substantially increases bone mineral density and reduces fracture rates at all skeletal sites for as long as it is administered.
A. Anastasilakis, P. Makras, M. Yavropoulou, G. Tabacco, A. Naciu, A. Palermo   +5 more
semanticscholar   +1 more source

Effects of RANKL-Targeted Therapy in Immunity and Cancer. [PDF]

, 2014
The role of the receptor activator of nuclear factor-κB ligand (RANKL)/RANK system is well characterized within bone, where RANKL/RANK signaling mediates osteoclastogenesis and bone resorption.
Cheng, Michael L, Fong, Lawrence
core   +2 more sources